Dierikx, Thomas H.
Deianova, Nancy
Groen, Jip
Vijlbrief, Daniel C.
Hulzebos, Christian
de Boode, Willem P.
d’Haens, Esther J.
Cossey, Veerle
Kramer, Boris W.
van Weissenbruch, Mirjam M.
de Jonge, Wouter J.
Benninga, Marc A.
van den Akker, Chris H.
van Kaam, Anton H.
de Boer, Nanne K. H.
Visser, Douwe H.
Niemarkt, Hendrik J.
de Meij, Tim G. J.
Funding for this research was provided by:
Stichting Zeldzame Ziekten Fonds
European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement (814168, 814168)
Article History
Received: 28 April 2022
Revised: 14 July 2022
Accepted: 23 July 2022
First Online: 4 August 2022
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. The study protocol was reviewed and approved by the local institutional review board of Amsterdam UMC, location VUmc, Amsterdam, the Netherlands (approval number A2020.190).
: Written informed consent was obtained from both parents and/or legal guardians of all infants.
: N. de Boer has served as a speaker for AbbVie, Takeda, and MSD. He has served as a consultant and principal investigator for Takeda and/or TEVA Pharma B.V. He has received research grants from Dr. Falk, MLDS, and Takeda. All outside the submitted work. All other authors declare not to have relevant financial or non-financial interests to disclose.